Emerald Mutual Fund Advisers Trust’s Amylyx Pharmaceuticals AMLX Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-656,530	Closed	-$9.66M	–	229
2023 Q4	$9.66M	Sell	656,530 -24,780	-4%	-$380K	0.51%	78
2023 Q3	$12.5M	Buy	681,310 +1,275	+0.2%	+$27K	0.75%	59
2023 Q2	$14.7M	Sell	680,035 -109,556	-14%	-$2.96M	0.8%	60
2023 Q1	$23.2M	Buy	789,591 +134,576	+21%	+$4.68M	1.37%	16
2022 Q4	$24.2M	Buy	655,015 +183,128	+39%	+$6.5M	1.5%	12
2022 Q3	$13.3M	Buy	+471,887	New	+$11.8M	0.84%	50

Other funds holding AMLX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's AMLX Position: Q1 2024 in Review

Emerald Mutual Fund Advisers Trust sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2024, closing a stake of 656,530 shares — an estimated $9.66M sold.

Emerald Mutual Fund Advisers Trust first reported a position in AMLX in Q3 2022 and held it in 6 quarters. The position peaked at $24.2M in Q4 2022. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

Emerald Mutual Fund Advisers Trust reported no remaining Amylyx Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Emerald Mutual Fund Advisers Trust sold 656,530 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $9.66M.
Emerald Mutual Fund Advisers Trust first reported a position in Amylyx Pharmaceuticals in Q3 2022 and held it in 6 quarters.
Emerald Mutual Fund Advisers Trust's Amylyx Pharmaceuticals position peaked at $24.2M in Q4 2022.
143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2024, filed 8 May 2024.